Adcetris market seen growing to $2.12 million by 2030

The Business Research Company says the global Adcetris market is expanding on rising cancer cases, demand for targeted therapies and broader use in oncology. The report projects the market will grow from $1.52 million in 2026 to $2.12 million by 2030, with North America leading in 2025 and Asia-Pacific expected to grow fastest.

Why it matters: - The Adcetris market is tied to demand for targeted cancer treatment. - Growth in CD30-positive cancers and broader oncology spending can expand use of antibody-drug conjugates. - The market outlook points to continued adoption of personalized medicine and oncology biologics.

What happened: - The Business Research Company released its Adcetris Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the market at $1.52 million in 2026, up from $1.4 million in 2025. - The report projects the market will reach $2.12 million by 2030. - The report says North America held the largest market share in 2025. - The report forecasts Asia-Pacific will post the fastest growth in the coming years. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available online. - The full report is also available online.

The details: - The report says the market grew on advances in monoclonal antibody research. - The report links growth to a rising number of Hodgkin lymphoma cases. - The report cites unmet treatment needs in relapsed cancers as a growth factor. - The report points to successful clinical outcomes for targeted therapies. - The report also cites regulatory approvals for antibody-drug conjugates. - Looking ahead, the report says expansion into new indications will support growth. - The report also points to increased investment in oncology biologics. - Wider adoption of personalized medicine is another projected driver. - Rising healthcare spending on cancer and better ADC manufacturing scalability are also expected to support the market. - Adcetris targets CD30-positive cancer cells and delivers a cytotoxic agent directly to tumors. - The targeted approach is designed to improve treatment outcomes and reduce side effects. - The therapy is used for Hodgkin lymphoma and other CD30-expressing cancers. - American Cancer Society data from January 2023 showed 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States. - The report says those numbers underscore the need for effective therapies such as Adcetris. - The 2026 report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Between the lines: - The report frames Adcetris as part of a larger shift toward precision oncology. - The fastest-growing regions and forecast indicators suggest demand is becoming more global, not just concentrated in mature markets. - The emphasis on scalability and new indications suggests the market story is moving from research progress to broader commercial expansion.

What's next: - The market is expected to keep expanding through 2030 as oncology pipelines and personalized medicine adoption grow. - Further uptake will likely depend on additional indications, manufacturing capacity and healthcare spending trends. - The Business Research Company invites readers to contact its expert team for more information through the company’s published contact details. - The report’s social and website links are available on the company’s announcement.